Article Text

Download PDFPDF
Original article
Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study
  1. Teresa Requena1,
  2. Maria Teresa Martín2,
  3. Trinidad Desongles3,
  4. Isabel Castillo4,
  5. Laura Lorente5,
  6. Maria Yébenes6,
  7. and the EUPTHEA Group
  1. 1EUPTHEA, Madrid, Spain
  2. 2Pharmacy Service, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
  3. 3Pharmacy Service, Hospital Universitario Virgen del Rocío, Sevilla, Spain
  4. 4Pharmacy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  5. 5Pharmacy Service, Hospital Universitario La Fe, Valencia, Spain
  6. 6Pharmacoeconomics and Outcomes Research Iberia, Madrid, Spain
  1. Correspondence to Dr Teresa Requena, EUPTHEA, C/Santa Cruz de Marcenado 7, Madrid 28015, Spain; teresa.requenac{at}


Objective To study and compare the prescription pattern for antivirals to treat chronic hepatitis B in Spain and its autonomous communities in 2009.

Methods Cross-sectional study, via hospital pharmacy services, of a non-co-infected adult population treated for hepatitis B infection in the previous 6 months. A Spanish Hospital Pharmacy Society website application was used for data collection. The statistical program PASW 18.0 was used to analyse data for Spain (percentage) and for its autonomous communities (percentage, autonomous community percentage range).

Results The study included 2614 patients from 34 hospitals in all the Spanish autonomous communities except the Canary Islands, La Rioja, Ceuta and Melilla. Over three-quarters (76.1%) of the patients received monotherapy, and the remainder received combination therapy; the equivalent percentage ranges for the autonomous communities were 57.0–79.8% and 20.2–43.0%, respectively. Use of the different antivirals (autonomous community percentage ranges in parentheses) was as follows: lamivudine, 34.8% (27.4–48.3%); entecavir, 25.8% (18.5–32.7%); adefovir dipivoxil, 21.0% (10.3–26.5%); tenofovir, 16.0% (5.9–21.4%); pegylated interferon α-2a, 1.7% (0.3–4.4%); and telbivudine, 0.8% (0.0–1.5%). The most commonly used combinations (autonomous community percentage ranges in parentheses) were as follows: lamivudine–adefovir dipivoxil, 60.4% (42.2–77.9%); lamivudine–tenofovir, 21.9% (6.5–35.2%); and entecavir–adefovir dipivoxil, 7.3% (0.0–14.8%). The monotherapy use profile for Castilla-Leon was different from those of the other autonomous communities.

Conclusions Monotherapy was the most commonly used treatment regimen for hepatitis B. Lamivudine was the most widely used drug for monotherapy, and lamivudine with adefovir dipivoxil was the most common combination.

  • Clinical Pharmacy
  • Epidemiology
  • Public Health
  • Virology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.